课题基金 / 基金详情

IGF::OT::IGF SEER LINKED VIRTUAL TISSUE REPOSITORY (VTR)

IGF::OT::IGF SEER LINKED VIRTUAL TISSUE REPOSITORY (VTR)
IGF::OT::IGF SEER 链接虚拟组织存储库 (VTR)
批准号:
9162035
负责人:
ROSEMARY CRESS
金额:
$20.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-11 至 2017-09-10

项目摘要

项目成果

ROSEMARY CRESS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program is interested in developing a SEER-linked Virtual Tissue Repository (VTR). A SEER VTR, with its population representativeness and large sampling frame would be a unique resource for assembling robust collections of biospecimens even for rare tumors and outcomes. SEER demographic and clinical data can be augmented with custom annotation of data including detailed chemotherapy, time to recurrence, and body mass index. The objectives of the VTR Pilot Study are to assess the ability of SEER Registries To serve as a resource for biospecimen research To locate cases with biospecimens in pathology laboratories and determine the requirements to retrieve those biospecimens To provide custom annotation of specified data items The VTR Pilot will also capture costs to identify and annotate these biospecimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NCI PATTERNS OF CARE (POC)/QUALITY OF CARE STUDY: DIAGNOSIS YEAR 2019 (URINARY BLADDER CANCER AND KIDNEY CANCER)
  • 批准号:
    10472113
  • 项目类别:
  • 资助金额:
    $34.35万
  • 财政年份:
    2021
  • 负责人:
    ROSEMARY CRESS
  • 依托单位:
NCI Patterns of Care (POC)/Quality of Care Study: Diagnosis Years 2017(NSCLC) and 2018 (NSCLC and Melanoma)
  • 批准号:
    10023828
  • 项目类别:
  • 资助金额:
    $22.55万
  • 财政年份:
    2019
  • 负责人:
    ROSEMARY CRESS
  • 依托单位:
SEER CORE INFRASTRUCTURE SUPPORT
  • 批准号:
    10610294
  • 项目类别:
  • 资助金额:
    $418.18万
  • 财政年份:
    2018
  • 负责人:
    ROSEMARY CRESS
  • 依托单位:
SEER CORE INFRASTRUCTURE SUPPORT
  • 批准号:
    10462122
  • 项目类别:
  • 资助金额:
    $399.15万
  • 财政年份:
    2018
  • 负责人:
    ROSEMARY CRESS
  • 依托单位:
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data